部分中文SUPRAX处方资料（仅供参考）
英文药名: Suprax (cefixime suspension)
中文药名: 头孢克肟口服悬浮液
药品名称
【通用名称】头孢克肟
【英文名称】Cefixime
【成份／规格】
头孢克肟。
头孢克肟悬浮液100mg/5ml。
头孢克肟片 50mg;100mg;200mg;400mg。
药理毒理
对革兰氏阳性菌和革兰氏阴性菌均有较广泛的抗菌作用，特别是对革兰氏阳性菌中的链球菌属、肺炎球菌、革兰氏阴性菌中的淋球菌、伯雷汉氏菌属、大肠杆菌、沙雷氏杆菌属、克雷白氏菌属、变形杆菌属、流感杆菌等较其它口服头孢类有较强的抗菌能力，其作用方式为杀菌。
由于本品对各种细菌所产生的β-内酰胺酶极其稳定，因而对产生β-内酰胺酶的细菌也具有优异的抗菌力。
本品的作用机制主要是阻止细菌细胞壁的合成。
适应症
广谱抗菌素。对链球菌属、肺炎球菌、淋球菌、伯雷汉氏菌属、大肠杆菌、沙雷氏杆菌属、克雷白氏杆菌属、变形杆菌属、流感杆菌所引起的感染症有效。主要用于治疗支气管炎、支气管扩张合并感染、慢性呼吸道疾患继发感染、肺炎、肾盂肾炎、膀胱炎、淋菌性尿道炎、胆囊炎、胆管炎、猩红热、中耳炎、副鼻窦炎。
用法用量
口服。成人和体重30公斤以上的儿童一次50～100mg，一日2次。重症可增加到一次0.2g，一日2次。
任何疑问，请遵医嘱！
不良反应
主要为腹泻、粪便异常、头疼、恶心、腹痛、皮疹等，极少数患者GPT、GOT升高。
禁忌
对本品或头孢菌素类抗菌素有过敏史者禁用。
注意事项
对青霉素过敏者、过敏体质的患者、高度肾功能损害的患者、对不能很好进食或非经口摄取营养者、高龄者、恶液质等患者、孕妇、新生儿慎用。
SUPRAX(cefixime) for Oral Suspension, USP

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Suprax (cefixime) for Oral Suspension and other antibacterial drugs, Suprax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
DRUG DESCRIPTION Suprax (cefixime) for Oral Suspension is a semisynthetic, cephalosporin antibiotic for oral administration. After reconstitution each teaspoonful (5mL) of suspension contains 100 mg of cefixime as the trihydrate. In addition, the suspension contains the following inactive ingredients: strawberry flavor, sodium benzoate, sucrose, colloidal silicon dioxide and xanthan gum. INDICATIONS To reduce the development of drug resistant bacteria and maintain the effectiveness of Suprax (cefixime) for Oral Suspension and other
antibacterial drugs, Suprax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Suprax is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Uncomplicated Urinary Tract Infections caused by Escherichia coli and Proteus mirabilis. Otitis Media caused by Haemophilus influenzae
(beta-lactamase positive and negative strains), Moraxella (Branhamella) catarrhalis, (most of which are beta-lactamase positive) and S. pyogenes*. Note: For information on otitis media caused by Streptococcus pneumoniae, see CLINICAL STUDIES section. Pharyngitis
and Tonsillitis, caused by S. pyogenes. Note: Penicillin is the usual drug of choice in the treatment of S. pyogenes infections, including the prophylaxis of rheumatic fever. Suprax is generally effective in the eradication of S. pyogenes from the nasopharynx however, data establishing the efficacy of Suprax in the subsequent prevention of rheumatic fever are not available. Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis, caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains). Uncomplicated gonorrhea(cervical/urethral), caused by Neisseria gonorrhoeae(penicillinase-and non-penicillinase- producing strains). Appropriate cultures and susceptibility studies should be performed to determine the causative organism and its susceptibility to cefixime however, therapy may be started while awaiting the results of these studies. Therapy should be adjusted, if necessary, once these results are known. SIDE EFFECTS Most of adverse reactions observed in clinical trials were of a mild and transient nature. Five percent (5%) of patients in the U.S. trials discontinued therapy because of drug-related adverse reactions.
The most commonly seen adverse reactions in U.S. trials of the tablet formulation were gastrointestinal events, which were reported in 30% of adult patients on either the BID or the QD regimen. Clinically mild gastrointestinal side effects occurred in 20% of all patients, moderate events occurred in 9% of all patients and severe adverse reactions occurred in 2% of all patients. Individual event rates included diarrhea 16%, loose or frequent stools 6%, abdominal pain 3%, nausea 7%, dyspepsia 3%, and flatulence 4%. The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools, in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients receiving tablets. These symptoms usually responded to symptomatic therapy or ceased when cefixime was discontinued.              
---------------------------------------------------------------
产地国家: 美国
原产地英文商品名:
SUPRAX SUSPENSION 500mg/5ml 20mls/bottle
原产地英文药品名:
CEFIXIME
中文参考商品译名:
SUPRAX混悬剂 500毫克/5毫升 20毫升/瓶
中文参考药品译名:
头孢克肟
生产厂家中文参考译名:
LUPIN PHARMS
生产厂家英文名:
LUPIN PHARMS